Company leader
Mor Brokman Meltzer
Co-founder and CEO
Opmed
Mor Brokman Meltzer is co-founder and chief executive of Opmed, a company that makes AI software for scheduling operating rooms and other hospital resources. An Israeli researcher with a doctorate on the complexity of work plans, she turned that research into software that hands hospital schedulers optimized OR schedules and block plans to choose from.
A first startup and a PhD
She worked for Israel's Ministry of Defense and founded a startup before Opmed. That company did not succeed, and the lesson she took from it was about product-market fit: she said yes to too many customers in too many industries, and its product could not fit them all.
She then went into academia and earned a PhD at Bar-Ilan University, near Tel Aviv, on resource management and the complexity of work plans. The doctorate gave her a specialty to bring back to company-building.
Starting Opmed with operating rooms
She co-founded Opmed with Avi Paz and Baruch Barzel during the COVID-19 pandemic, wanting to apply her research to an urgent problem. She spoke with hospital leaders in Israel, then the UK, then the United States, and settled on hospital scheduling because the problem repeated across many hospitals and was painful and valuable enough to build a company around. Opmed's software forecasts case length and surgical demand and generates alternative OR schedules that weigh staff, equipment, and surgeon preferences, so planners choose among options instead of building a schedule by hand.
Opmed raised a $15 million Series A in 2024. "Our mission is to support hospitals grappling with staff shortages and other critical issues by providing them a less labor-intensive, more effective way to perform at their best," she told Calcalist, the Israeli business daily, at the time.
Building the U.S. business from Boston
She moved to Boston to build Opmed's U.S. business while Paz and Barzel lead its work in Israel. Her reasoning is that a founder needs to be where the customers are, because U.S. healthcare sales are slow and involve many stakeholders, and being close to hospitals makes it easier to meet them and earn their trust.